Cigna Investments Inc. New Has $1.39 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Cigna Investments Inc. New increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.9% during the second quarter, Holdings Channel reports. The firm owned 10,762 shares of the pharmaceutical company’s stock after buying an additional 504 shares during the period. Cigna Investments Inc. New’s holdings in Vertex Pharmaceuticals were worth $1,387,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Korea Investment CORP boosted its position in Vertex Pharmaceuticals by 225.3% in the first quarter. Korea Investment CORP now owns 950 shares of the pharmaceutical company’s stock worth $104,000 after buying an additional 658 shares in the last quarter. Guardian Life Insurance Co. of America boosted its position in Vertex Pharmaceuticals by 0.6% in the first quarter. Guardian Life Insurance Co. of America now owns 956 shares of the pharmaceutical company’s stock worth $105,000 after buying an additional 6 shares in the last quarter. FUKOKU MUTUAL LIFE INSURANCE Co boosted its position in Vertex Pharmaceuticals by 7.1% in the first quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 1,500 shares of the pharmaceutical company’s stock worth $164,000 after buying an additional 100 shares in the last quarter. State of Alaska Department of Revenue acquired a new position in Vertex Pharmaceuticals during the second quarter worth about $197,000. Finally, Sterling Global Strategies LLC acquired a new position in Vertex Pharmaceuticals during the first quarter worth about $200,000. 93.13% of the stock is owned by institutional investors and hedge funds.
Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at 152.58 on Thursday. The stock has a market cap of $38.47 billion, a PE ratio of 146.57 and a beta of 1.77. Vertex Pharmaceuticals Incorporated has a one year low of $71.46 and a one year high of $167.86. The company’s 50-day moving average price is $142.94 and its 200-day moving average price is $114.68.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.33. Vertex Pharmaceuticals had a return on equity of 4.64% and a net margin of 12.05%. The business had revenue of $544.10 million during the quarter, compared to analyst estimates of $489.95 million. During the same quarter in the previous year, the company posted $0.24 earnings per share. Vertex Pharmaceuticals’s revenue for the quarter was up 26.1% on a year-over-year basis. Equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post $1.59 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Cigna Investments Inc. New Has $1.39 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/cigna-investments-inc-new-has-1-39-million-position-in-vertex-pharmaceuticals-incorporated-nasdaqvrtx/1469352.html.
A number of research firms have issued reports on VRTX. Raymond James Financial, Inc. upgraded Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $181.00 target price on the stock in a research report on Wednesday, July 19th. J P Morgan Chase & Co set a $175.00 target price on Vertex Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, July 19th. Oppenheimer Holdings, Inc. lifted their target price on Vertex Pharmaceuticals from $150.00 to $175.00 and gave the company an “outperform” rating in a research report on Thursday, July 27th. Vetr upgraded Vertex Pharmaceuticals from a “strong sell” rating to a “sell” rating and set a $102.09 target price on the stock in a research report on Monday, May 15th. Finally, Zacks Investment Research upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 target price on the stock in a research report on Tuesday, July 4th. Five equities research analysts have rated the stock with a hold rating, twenty-two have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $162.88.
In other Vertex Pharmaceuticals news, EVP Stuart A. Arbuckle sold 70,969 shares of the business’s stock in a transaction dated Friday, June 2nd. The stock was sold at an average price of $128.06, for a total transaction of $9,088,290.14. Following the completion of the sale, the executive vice president now owns 145,061 shares of the company’s stock, valued at $18,576,511.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Sangeeta N. Bhatia sold 1,176 shares of the business’s stock in a transaction dated Friday, June 2nd. The shares were sold at an average price of $128.44, for a total value of $151,045.44. Following the sale, the director now directly owns 5,129 shares of the company’s stock, valued at approximately $658,768.76. The disclosure for this sale can be found here. Insiders have sold 751,042 shares of company stock valued at $113,078,257 in the last three months. 1.80% of the stock is currently owned by corporate insiders.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.